CRISPR Therapeutics CRSP Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's operating lease right-of-use assets in other assets?
- CRISPR Therapeutics (CRSP) reported operating lease right-of-use assets in other assets of $128.67M in Q1 2026.
- How has CRISPR Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- CRISPR Therapeutics's operating lease right-of-use assets in other assets decreased by 8.3% year-over-year, from $140.28M to $128.67M.
- What is the long-term trend for CRISPR Therapeutics's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's operating lease right-of-use assets in other assets has grown at a 21.0% compound annual growth rate (CAGR), from $50.87M to $131.72M.